Alkermes(US:ALKS) ZACKSยท2024-10-24 13:11Company Performance - Alkermes reported quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share, but showing an increase from $0.64 per share a year ago, resulting in an earnings surprise of -6.41% [1] - The company posted revenues of $378.14 million for the quarter ended September 2024, which was 2.06% below the Zacks Consensus Estimate and a decrease from $380.94 million year-over-year [1] - Over the last four quarters, Alkermes has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [1] Future Outlook - The immediate price movement of Alkermes' stock will largely depend on management's commentary during the earnings call and future earnings expectations [2] - The current consensus EPS estimate for the upcoming quarter is $0.78 on revenues of $377.63 million, while for the current fiscal year, the estimate is $2.69 on revenues of $1.51 billion [4] - The estimate revisions trend for Alkermes is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [4] Industry Context - The Medical - Biomedical and Genetics industry, to which Alkermes belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable industry outlook [5] - Alnylam Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.51 per share, reflecting a year-over-year change of -144.4%, with revenues anticipated to be $529.8 million, down 29.4% from the previous year [5]